Teamwork Financial Advisors LLC Decreases Stock Holdings in Novo Nordisk A/S $NVO

Key Points

• Teamwork Financial Advisors cut its Novo Nordisk stake by 94.9% in the second quarter, selling 95,033 shares and retaining 5,091 shares valued at approximately $244,000.
• Novo Nordisk raised its full-year sales and profit outlook, supported by Wegovy pill demand and stronger-than-expected quarterly results, although pill sales narrowly missed forecasts and competition from Eli Lilly remains a concern.
• Analyst sentiment remains cautious, with the stock carrying a consensus “Hold” rating and a $65.81 average price target; NVO recently traded at $47.21, while institutional investors own 11.54% of the company.

Teamwork Financial Advisors LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 94.9% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,091 shares of the company's stock after selling 95,033 shares during the quarter. Teamwork Financial Advisors LLC's holdings in Novo Nordisk A/S were worth $244,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. Quotient Wealth Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 2.0% in the 4th quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company's stock worth $463,000 after buying an additional 177 shares during the period. Certuity LLC increased its stake in shares of Novo Nordisk A/S by 3.6% during the fourth quarter. Certuity LLC now owns 5,052 shares of the company's stock valued at $257,000 after buying an additional 177 shares during the period. Oakworth Capital Inc. raised its holdings in shares of Novo Nordisk A/S by 41.6% in the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company's stock valued at $31,000 after acquiring an additional 182 shares in the last quarter. True North Advisors LLC lifted its stake in Novo Nordisk A/S by 3.9% in the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company's stock worth $270,000 after acquiring an additional 199 shares during the period. Finally, Revolve Wealth Partners LLC lifted its stake in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after acquiring an additional 200 shares during the period. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk raised its full-year sales and profit outlook for the second time this year. Management cited accelerating demand for the Wegovy pill and continued growth in obesity care, while recent coverage noted that second-quarter revenue and earnings exceeded analyst expectations. NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
• Positive Sentiment: A Texas judge dismissed antitrust claims alleging Novo and Eli Lilly improperly restricted access to compounded GLP-1 weight-loss drugs. The ruling reduces a potential legal overhang for Novo’s obesity-drug business. Lilly and Novo Win a Key GLP-1 Antitrust Fight
• Positive Sentiment: The company declared a dividend of $0.5786 per share for investors of record August 17, payable August 25. The payout may provide some support for income-focused investors, although the reported yield in the announcement appears anomalous.
• Neutral Sentiment: CEO Mike Doustdar and CFO Karina Hertmann are emphasizing a reset in investor expectations and a more disciplined approach to growth after a difficult period. Their comments could help rebuild confidence, but they also underscore pressure to improve execution and regain momentum. Novo Nordisk CEO resets expectations for Wegovy's explosive growth
• Neutral Sentiment: Novo appointed Omnicom as its U.S. media-buying agency of record, a move intended to strengthen marketing for its obesity portfolio but unlikely to materially affect near-term earnings. Novo Nordisk makes Omnicom agency of record for US media buying
• Negative Sentiment: Wegovy pill sales totaled about $497 million, narrowly missing forecasts. Investors remain concerned that the launch is not progressing rapidly enough to offset slowing momentum in Novo’s injectable obesity products. Novo Nordisk CEO addresses investor expectations after Wegovy pill sales miss forecasts
• Negative Sentiment: Eli Lilly’s stronger obesity-drug performance is widening the perceived competitive gap. Analysts also point to U.S. pricing pressure, patent losses, slower product development and pipeline impairments as reasons the raised outlook has not fully changed the negative narrative around Novo’s obesity business. The divide between Eli Lilly and Novo Nordisk is widening

Wall Street Analysts Forecast Growth

Several research firms have recently commented on NVO. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, June 20th. HSBC reissued a "hold" rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Nordea Equity Research raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Friday, June 19th. BMO Capital Markets restated a "market perform" rating and set a $47.00 target price on shares of Novo Nordisk A/S in a report on Thursday. Finally, Citigroup reaffirmed a "neutral" rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Five investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $65.81.

Novo Nordisk A/S Trading Up 2.7%

Novo Nordisk A/S stock opened at $47.21 on Friday. The stock has a 50-day moving average of $47.00 and a two-hundred day moving average of $45.02. The stock has a market cap of $210.77 billion, a PE ratio of 11.54, a price-to-earnings-growth ratio of 4.16 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $64.16.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The company had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. On average, research analysts anticipate that Novo Nordisk A/S will post 3.41 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be issued a $0.5786 dividend. This represents a yield of 254.0%. The ex-dividend date is Monday, August 17th. Novo Nordisk A/S's dividend payout ratio is 42.79%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source